STEREOSELECTIVITY AND REGIOSELECTIVITY OF HEPATIC OXIDATION IN MAN - EFFECT OF THE DEBRISOQUINE SPARTEINE PHENOTYPE ON BUFURALOL HYDROXYLATION

被引：37

作者：

DAYER, P

LEEMANN, T

KUPFER, A

KRONBACH, T

MEYER, UA

机构：

[1] UNIV GENEVA,DEPT MED,CLIN PHARMACOL UNIT,CH-1211 GENEVA 4,SWITZERLAND

[2] UNIV BERN,DEPT CLIN PHARMACOL,CH-3000 BERN,SWITZERLAND

[3] UNIV BASEL,DEPT PHARMACOL,CH-4051 BASEL,SWITZERLAND

来源：

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 1986年 / 31卷 / 03期

关键词：

D O I：

10.1007/BF00981130

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：313 / 318

页数：6

共 25 条

[1] STEREOCHEMISTRY, A BASIS FOR SOPHISTICATED NONSENSE IN PHARMACOKINETICS AND CLINICAL-PHARMACOLOGY
ARIENS, EJ
[J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 26 (06) : 663 - 668
[2] BOOBIS AR, 1983, MOL PHARMACOL, V23, P474
[3] GENETIC-POLYMORPHISM IN DRUG OXIDATION - INVITRO STUDIES OF HUMAN DEBRISOQUINE 4-HYDROXYLASE AND BUFURALOL 1'-HYDROXYLASE ACTIVITIES
BOOBIS, AR
MURRAY, S
HAMPDEN, CE
DAVIES, DS
[J]. BIOCHEMICAL PHARMACOLOGY, 1985, 34 (01) : 65 - 71
[4] EVIDENCE FOR AN ENZYMATIC DEFECT IN THE 4-HYDROXYLATION OF DEBRISOQUINE BY HUMAN-LIVER
DAVIES, DS
KAHN, GC
MURRAY, S
BRODIE, MJ
BOOBIS, AR
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 11 (01) : 89 - 91
[5] CHARACTERIZATION OF A COMMON GENETIC-DEFECT OF CYTOCHROME-P-450 FUNCTION (DEBRISOQUINE-SPARTEINE TYPE POLYMORPHISM) - INCREASED MICHAELIS CONSTANT (KM) AND LOSS OF STEREOSELECTIVITY OF BUFURALOL 1'-HYDROXYLATION IN POOR METABOLIZERS
DAYER, P
GASSER, R
GUT, J
KRONBACH, T
ROBERTZ, GM
EICHELBAUM, M
MEYER, UA
[J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1984, 125 (01) : 374 - 380
[6] STERIC CONFIGURATION AND POLYMORPHIC OXIDATION OF LIPOPHILIC BETA-ADRENOCEPTOR BLOCKING-AGENTS - INVIVO INVITRO CORRELATIONS
DAYER, P
LEEMANN, T
GUT, J
KRONBACH, T
KUPFER, A
FRANCIS, R
MEYER, UA
[J]. BIOCHEMICAL PHARMACOLOGY, 1985, 34 (03) : 399 - 400
[7] INTERINDIVIDUAL VARIATION OF BETA-ADRENOCEPTOR BLOCKING-DRUGS, PLASMA-CONCENTRATION AND EFFECT - INFLUENCE OF GENETIC STATUS ON BEHAVIOR OF ATENOLOL, BOPINDOLOL AND METOPROLOL
DAYER, P
LEEMANN, T
MARMY, A
ROSENTHALER, J
[J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 28 (02) : 149 - 153
[8] EFFECT OF OXIDATIVE POLYMORPHISM (DEBRISOQUINE SPARTEINE TYPE) ON HEPATIC 1ST-PASS METABOLISM OF BUFURALOL
DAYER, P
BALANT, L
KUPFER, A
STRIBERNI, R
LEEMANN, T
[J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 28 (03) : 317 - 320
[9] CONTRIBUTION OF THE GENETIC STATUS OF OXIDATIVE-METABOLISM TO VARIABILITY IN THE PLASMA-CONCENTRATIONS OF BETA-ADRENOCEPTOR BLOCKING-AGENTS
DAYER, P
BALANT, L
KUPFER, A
COURVOISIER, F
FABRE, J
[J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 24 (06) : 797 - 799
[10] DEFECTIVE HYDROXYLATION OF BUFURALOL ASSOCIATED WITH SIDE-EFFECTS OF THE DRUG IN POOR METABOLIZERS
DAYER, P
KUBLI, A
KUPFER, A
COURVOISIER, F
BALANT, L
FABRE, J
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 13 (05) : 750 - 752

← 1 2 3 →